CN101506156A - 对GlyT1转运蛋白具有活性的吡咯烷衍生物 - Google Patents

对GlyT1转运蛋白具有活性的吡咯烷衍生物 Download PDF

Info

Publication number
CN101506156A
CN101506156A CNA2007800312340A CN200780031234A CN101506156A CN 101506156 A CN101506156 A CN 101506156A CN A2007800312340 A CNA2007800312340 A CN A2007800312340A CN 200780031234 A CN200780031234 A CN 200780031234A CN 101506156 A CN101506156 A CN 101506156A
Authority
CN
China
Prior art keywords
phenyl
trifluoromethyl
methyl
benzamide
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800312340A
Other languages
English (en)
Chinese (zh)
Inventor
克莱尔·L·安德顿
戴维·克拉费姆
特雷弗·R·基尔
利安达·J·金顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN101506156A publication Critical patent/CN101506156A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2007800312340A 2006-06-22 2007-06-20 对GlyT1转运蛋白具有活性的吡咯烷衍生物 Pending CN101506156A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0612420.0 2006-06-22
GBGB0612420.0A GB0612420D0 (en) 2006-06-22 2006-06-22 Compounds

Publications (1)

Publication Number Publication Date
CN101506156A true CN101506156A (zh) 2009-08-12

Family

ID=36803732

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800312340A Pending CN101506156A (zh) 2006-06-22 2007-06-20 对GlyT1转运蛋白具有活性的吡咯烷衍生物

Country Status (23)

Country Link
US (1) US20080070973A1 (enExample)
EP (1) EP2041082B1 (enExample)
JP (1) JP2009541261A (enExample)
KR (1) KR20090019847A (enExample)
CN (1) CN101506156A (enExample)
AR (1) AR061554A1 (enExample)
AT (1) ATE444288T1 (enExample)
AU (1) AU2007263058A1 (enExample)
BR (1) BRPI0713311A2 (enExample)
CA (1) CA2655399A1 (enExample)
CL (1) CL2007001808A1 (enExample)
CR (1) CR10498A (enExample)
DE (1) DE602007002642D1 (enExample)
EA (1) EA200970044A1 (enExample)
ES (1) ES2333918T3 (enExample)
GB (1) GB0612420D0 (enExample)
IL (1) IL195633A0 (enExample)
MA (1) MA30522B1 (enExample)
NO (1) NO20085412L (enExample)
PE (1) PE20080380A1 (enExample)
TW (1) TW200817322A (enExample)
WO (1) WO2007147831A1 (enExample)
ZA (1) ZA200810009B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068388A (zh) * 2010-08-09 2013-04-24 霍夫曼-拉罗奇有限公司 Glyt1化合物与抗精神病药的组合

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
WO2008155334A2 (en) * 2007-06-20 2008-12-24 Glaxo Group Limited Improved process of amide formation
SG186885A1 (en) 2010-06-04 2013-02-28 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2019073052A1 (en) 2017-10-13 2019-04-18 Treeway Tw001 B.V. EDARAVONE SALT

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2746959A (en) * 1953-06-02 1956-05-22 American Home Prod Diphenylethylenediamine-penicillin salt
US3145209A (en) * 1961-07-31 1964-08-18 Olin Mathieson Substituted aminophenyl-ethylamine derivatives
NZ237443A (en) * 1990-04-10 1993-11-25 Asta Medica Ag Phenalkylethylenediamine and aminomethyltetra hydroisoquinoline derivatives, platinum (ii) and (iv) complexes, methods of preparation and pharmaceutical compositions
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
PE20061156A1 (es) * 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068388A (zh) * 2010-08-09 2013-04-24 霍夫曼-拉罗奇有限公司 Glyt1化合物与抗精神病药的组合

Also Published As

Publication number Publication date
US20080070973A1 (en) 2008-03-20
BRPI0713311A2 (pt) 2012-03-06
GB0612420D0 (en) 2006-08-02
AU2007263058A1 (en) 2007-12-27
AR061554A1 (es) 2008-09-03
DE602007002642D1 (de) 2009-11-12
IL195633A0 (en) 2009-09-01
ES2333918T3 (es) 2010-03-02
NO20085412L (no) 2009-01-22
ZA200810009B (en) 2009-11-25
CL2007001808A1 (es) 2008-01-18
CA2655399A1 (en) 2007-12-27
EP2041082A1 (en) 2009-04-01
WO2007147831A1 (en) 2007-12-27
MA30522B1 (fr) 2009-06-01
EA200970044A1 (ru) 2009-04-28
TW200817322A (en) 2008-04-16
EP2041082B1 (en) 2009-09-30
ATE444288T1 (de) 2009-10-15
JP2009541261A (ja) 2009-11-26
CR10498A (es) 2009-03-20
KR20090019847A (ko) 2009-02-25
PE20080380A1 (es) 2008-05-31

Similar Documents

Publication Publication Date Title
CN101903342B (zh) 取代的n-苯基-吡咯烷基甲基吡咯烷酰胺及其作为组胺h3受体调节剂的治疗用途
CN101321736B (zh) 对m1受体具有活性的化合物及其在医药中的用途
JP2009530247A (ja) Ｎ−フェニル−２−オキソ−１，４−ジアザスピロ［４．５］デカ−３−エン−１−イルアセトアミド誘導体およびグリシン輸送体阻害剤としてのそれらの使用
JP2010517964A (ja) ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
JP2009533385A (ja) １−（２−アリール−２−オキソエチル）−３−フェニル−１，４−ジアザスピロ［４，５］デク−３−エン−２−オン誘導体およびグリシントランスポーター阻害薬としてのそれらの使用
AU2014336258B2 (en) Piperazine derivatives and the use thereof as medicament
WO2011036885A1 (ja) 複素環化合物
CN101506156A (zh) 对GlyT1转运蛋白具有活性的吡咯烷衍生物
KR20070091210A (ko) 글리신 수송 억제제
JP2009503006A (ja) ＧｌｙＴ１トランスポーター阻害剤ならびに神経および神経精神障害の治療におけるその使用
JP2008525403A (ja) グリシントランスポーター阻害化合物としての酸素含有複素環
JP2008525398A (ja) グリシン輸送阻害剤
JP2008525399A (ja) グリシン輸送阻害剤
JP2007533715A (ja) ＧｌｙＴ１阻害剤として用いるためのモルホリニルおよびピペリジニル基を有する化合物
JP2010517959A (ja) ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
JP2008525402A (ja) ２−アミノ−１−フェニルエチルカルボキサミド誘導体
JP2007533713A (ja) Ｎ−［４−４（４−モルホリニル）フェニル］−［（４−ピペリジニル）メチル］カルボキシアミド誘導体、およびグリシントランスポーター阻害薬としてのその使用
US20100016374A1 (en) Compounds Which Inhibit the Glycine Transporter and Uses Thereof
US20090227629A1 (en) Compounds having activity at the glycine transporter glyt1 and uses thereof
EP1789050A1 (en) Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
MX2009000106A (es) Derivados de pirrolidina que tienen actividad en el transportador glyti.
JP2007533714A (ja) Ｎ−［６−（４−モルホリニル）−３−ピリジニル］−２−（テトラヒドロ−２ｈ−ピラン−４−イル）−ｎ−［（１−｛［フェニル］メチル｝−４−ピペリジニル）メチル］アセトアミド誘導体および統合失調症などの精神病を治療するためのｇｌｙｔ１輸送阻害剤としての関連化合物
JP2010517960A (ja) ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
JP2010517965A (ja) ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
JP2012504574A (ja) Ｍ１受容体において活性を有する化合物およびその医薬における使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090812